Johnson & Johnson (JNJ): Director bought ~$147K

~$147K

Approx. value · 1,000 sh @ $147.22

1,000

Holds after · shares reported

Traded

Dec 12, 2024

Filed

Dec 12, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 29, 2024CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
2. Nov 8, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
3. Nov 22, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
4. Nov 25, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
5. Nov 26, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
6. Dec 6, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
7. Dec 10, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
8. Dec 12, 2024 · this disclosureInsiderDirector purchased ~$147K of JNJ shares in the open market

What came next

1. Dec 12, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
2. Dec 24, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
3. Dec 31, 2024CongressDisclosed sale of JNJ — reported range $100,001 - $250,000
4. Jan 8, 2025Congress · 1 personMembers of Congress: 4 purchases
5. Jan 16, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
6. Jan 21, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
7. Jan 23, 2025FDAFDA drug approval: Darzalex
8. Jan 23, 2025FDAFDA device clearance: MONARCH™ Platform (MON-000008)
9. Jan 24, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
10. Feb 5, 2025FDAFDA device clearance: GRYPHON™ X Anchor; HEALIX TRANSTEND™ Anchor
11. Feb 7, 2025InsiderCFO sold ~$2M of JNJ shares in the open market
12. Feb 18, 2025InsiderChair sold ~$63K of JNJ shares in the open market
13. Feb 24, 2025FDARecall: COR Disposable Kit, 8 mm. Cartilage Transplant System.
14. Feb 24, 2025FDARecall: COR Disposable Kit, 8 mm w/ Perpendicularity. Cartilage Transplant System.
15. Feb 24, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
16. Feb 25, 2025FDAFDA device clearance: ECHELON LINEAR™ Stapler 30mm Stapler (GTX30); ECHELON LINEAR™ Stapler 60mm Stapler (GTX60); ECHELON LINEAR™ Stapler 90mm Stapler (GTX90); ECHELON LINEAR™ Stapl…
17. Feb 25, 2025InsiderOfficer sold ~$1.16M of JNJ shares in the open market
18. Feb 28, 2025FDAFDA drug approval: Opsumit
19. Mar 4, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
20. Mar 5, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 119 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Johnson & Johnson

• House Clerk periodic transaction reportOct 5, 2026
• USAspending.gov award recordOct 5, 2026
• USAspending.gov award recordSep 24, 2026
• USAspending.gov award recordSep 22, 2026
• USAspending.gov award recordSep 21, 2026
• House Clerk periodic transaction reportSep 12, 2026

Everything OQRO holds on this company is on its JNJ page.